Quest Diagnostics (DGX) Tops Q2 EPS by 210c

Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $4.96, $2.10 better than the analyst estimate of $2.86. Revenue for the quarter came in at $2.55 billion versus the consensus estimate of $2.38 billion.

GUIDANCE:

Quest Diagnostics sees FY2021 EPS of $10.65-$11.35, versus the consensus of $11.13. Quest Diagnostics sees FY2021 revenue of $9.54-9.79 billion, versus the consensus of $9.45 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• JPMorgan cuts 2026 box office forecast on slow third quarter
• Delta Air shares slip despite strong outlook, Melius says